Delcath Systems (DCTH) Competitors $10.59 -0.16 (-1.49%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.58 0.00 (-0.05%) As of 08/1/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DCTH vs. CNMD, ENOV, SSII, CDRE, NVCR, AORT, ESTA, BLFS, TNDM, and PLSEShould you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include CONMED (CNMD), Enovis (ENOV), SS Innovations International (SSII), Cadre (CDRE), NovoCure (NVCR), Artivion (AORT), Establishment Labs (ESTA), BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry. Delcath Systems vs. Its Competitors CONMED Enovis SS Innovations International Cadre NovoCure Artivion Establishment Labs BioLife Solutions Tandem Diabetes Care Pulse Biosciences Delcath Systems (NASDAQ:DCTH) and CONMED (NYSE:CNMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Which has stronger earnings & valuation, DCTH or CNMD? CONMED has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDelcath Systems$37.21M9.91-$26.39M-$0.50-21.18CONMED$1.31B1.24$132.42M$3.5314.80 Is DCTH or CNMD more profitable? CONMED has a net margin of 8.31% compared to Delcath Systems' net margin of -26.38%. CONMED's return on equity of 14.60% beat Delcath Systems' return on equity.Company Net Margins Return on Equity Return on Assets Delcath Systems-26.38% -29.44% -20.75% CONMED 8.31%14.60%6.06% Do insiders and institutionals believe in DCTH or CNMD? 61.1% of Delcath Systems shares are held by institutional investors. 17.4% of Delcath Systems shares are held by insiders. Comparatively, 3.1% of CONMED shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to DCTH or CNMD? In the previous week, CONMED had 10 more articles in the media than Delcath Systems. MarketBeat recorded 12 mentions for CONMED and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.77 beat CONMED's score of 0.42 indicating that Delcath Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer DCTH or CNMD? Delcath Systems currently has a consensus target price of $24.00, indicating a potential upside of 126.63%. CONMED has a consensus target price of $59.80, indicating a potential upside of 14.45%. Given Delcath Systems' stronger consensus rating and higher probable upside, equities research analysts clearly believe Delcath Systems is more favorable than CONMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CONMED 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more risk and volatility, DCTH or CNMD? Delcath Systems has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. SummaryCONMED beats Delcath Systems on 9 of the 16 factors compared between the two stocks. Get Delcath Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DCTH vs. The Competition Export to ExcelMetricDelcath SystemsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$374.38M$6.70B$5.48B$9.53BDividend YieldN/A1.32%4.73%4.09%P/E Ratio-21.1820.9428.8923.83Price / Sales9.9154.12371.1466.13Price / CashN/A20.5035.4557.96Price / Book4.934.468.265.54Net Income-$26.39M$174.54M$3.25B$259.28M7 Day Performance-7.19%-5.27%-3.73%-4.67%1 Month Performance-15.35%-3.94%4.28%4.37%1 Year Performance30.42%8.26%25.85%17.90% Delcath Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DCTHDelcath Systems2.6982 of 5 stars$10.59-1.5%$24.00+126.6%+29.3%$374.38M$37.21M-21.1860Upcoming EarningsAnalyst UpgradeCNMDCONMED4.4037 of 5 stars$50.05-1.8%$62.20+24.3%-20.0%$1.58B$1.32B13.173,900News CoverageEarnings ReportAnalyst ForecastENOVEnovis2.9571 of 5 stars$27.36-0.7%$55.60+103.2%-44.7%$1.57B$2.11B-1.967,367Upcoming EarningsSSIISS Innovations InternationalN/A$7.20+0.3%N/AN/A$1.39B$20.65M0.004CDRECadre3.1447 of 5 stars$33.60-0.9%$37.50+11.6%-9.5%$1.38B$567.56M35.372,284Upcoming EarningsNVCRNovoCure4.4887 of 5 stars$11.64-3.3%$28.79+147.3%-47.1%$1.34B$605.22M-7.461,488News CoverageInsider TradeAORTArtivion2.3202 of 5 stars$31.32-0.3%$32.40+3.4%+15.7%$1.34B$388.54M-62.641,600Upcoming EarningsESTAEstablishment Labs1.7276 of 5 stars$42.48+0.2%$54.83+29.1%-2.8%$1.23B$166.02M-13.701,018Upcoming EarningsBLFSBioLife Solutions2.8055 of 5 stars$22.23-1.6%$31.00+39.5%-10.9%$1.08B$82.25M-76.65440Positive NewsUpcoming EarningsTNDMTandem Diabetes Care3.5015 of 5 stars$16.84+6.0%$32.71+94.3%-56.3%$1.06B$940.20M-6.062,650Positive NewsUpcoming EarningsPLSEPulse Biosciences3.9274 of 5 stars$15.21+1.9%$22.00+44.6%-2.3%$1.00B$700K0.00140News CoveragePositive News Related Companies and Tools Related Companies CONMED Competitors Enovis Competitors SS Innovations International Competitors Cadre Competitors NovoCure Competitors Artivion Competitors Establishment Labs Competitors BioLife Solutions Competitors Tandem Diabetes Care Competitors Pulse Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DCTH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
